A Phase 2, 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of SM04690 for the Treatment of Moderately to Severely Symptomatic Knee Osteoarthritis
Phase of Trial: Phase II
Latest Information Update: 24 Oct 2018
At a glance
- Drugs SM 04690 (Primary)
- Indications Osteoarthritis
- Focus Therapeutic Use
- Sponsors Samumed
- 24 Oct 2018 Results of patient reported outcomes for week 12 and 24, presented at the 82nd American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting
- 16 Oct 2018 According to a Samumed media release, data will be presented at the upcoming 2018 American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) Annual Meeting.
- 13 Aug 2018 Status changed from active, no longer recruiting to completed.